Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia: A Randomized Clinical Trial.

ABSTRACT:

Importance

Limited evidence supports multigenetic pharmacogenomics-guided treatment (MPGT) in schizophrenia.

Objective

To evaluate the clinical effectiveness of MPGT in schizophrenia in a randomized clinical trial (RCT).

Design, setting, and participants

This RCT was conducted from March 2020 to March 2022. Male Chinese Han inpatients aged 18 to 60 years diagnosed with schizophrenia with a Positive and Negative Symptom Scale (PANSS) score of 60 or more from 2 selected study hospitals were included. Patients and raters were masked to MPGT or treatment as usual (TAU) randomization.

Interventions

Participants were randomly assigned in a 1:1 ratio to receive either MPGT or TAU for 12 weeks.

Main outcomes and measures

The primary efficacy outcome was the perc

SUBMITTER: Kang Z 

PROVIDER: S-EPMC10559185 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature